Nov 14, 2012 by Max Macaluso and austin smith1 Reason to Buy Amarin Right Now, and 1 Reason to SellWhat are the bull and bear cases for Amarin today?
Nov 13, 2012 by Max Macaluso and Brenton FlynnSomething New for VIVUS Investors to Watch?Could weight-loss drug Qsymia have more uses?
Nov 13, 2012 by Max Macaluso and austin smithIs There a Big Opportunity for Amarin Investors?Does Vascepa have potential to be a top-selling drug?
Nov 11, 2012 by Max Macaluso and austin smithAmarin's Leadership: Who's at the Helm?Is this drugmaker's CEO the right leader?
Nov 9, 2012 by Max Macaluso and Brenton FlynnScience Amarin Investors Need to KnowWhat's the reason behind the NCE delay?
Nov 9, 2012 by Max Macaluso and Brenton FlynnCould Amarin Reject a Buyout?What did the market think about Amarin's Q3 update?
Nov 8, 2012 by Max MacalusoHot Off the Press: Amarin Earnings ReportWhat did Amarin report this quarter?
Nov 8, 2012 by Max Macaluso and austin smith1 Reason to Buy Amarin Right Now, and 1 Reason to SellShould you keep this drugmaker in your portfolio?
Nov 7, 2012 by Max MacalusoIs This the Right Partnership for Arena?Arena continues to search for international opportunities.
Nov 7, 2012 by Max MacalusoArena Earnings: How Did the Market React?Let's a take a look at Arena's Q3 Results
Nov 7, 2012 by Max MacalusoHot Off the Press: Arena Pharmaceuticals EarningsFirst impressions from this biotech's Q3 earnings report.
Nov 6, 2012 by Max MacalusoCan This Forgotten Drug Save VIVUS Investors?A look at VIVUS' erectile dysfunction drug.
Nov 6, 2012 by Max MacalusoVIVUS Earnings: Is This Biotech Ready for Prime Time?High expectations that this drugmaker wasn't ready to meet.
Nov 5, 2012 by Max Macaluso and Brenton FlynnVIVUS Earnings Report: 3 Critical Points to WatchWhat should investors focus on in tomorrow's press release?
Nov 4, 2012 by Max Macaluso and Dave WilliamsonIs MannKind Back on Track?What did MannKind report in its Q3 earnings?
Nov 3, 2012 by Max MacalusoHow Do You Solve a Problem Like Vascepa? Pharma company Amarin will report earnings next week. What should investors be watching for?
Nov 1, 2012 by Max MacalusoWorrying News for Abiomed Shareholders? Abiomed shares took a tumble today -- what happened?
Nov 1, 2012 by Max MacalusoWhy Is This Hidden Health Care Player Popping Today?A look at Gentiva's strong share price surge.
Nov 1, 2012 by Max MacalusoDoes Amarin Have the Right Management Team?Let's take an in-depth look at this pharma company's leadership.
